Otherwise, pan-TRK IHC may be utilized on other locally advanced or metastatic non-GIST soft tissue tumors with are negative for known or diagnostic molecular alterations to screen for NTRK fusions; followed by NGS for positive of IHC equivocal results [53]. The gene discussed is TPM3; the disease is gastrointestinal stromal tumor.